Medically reviewed by Richard N. Fogoros, MD Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that develops when ...

Medically reviewed by Laura Campedelli, DPT Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, potentially ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, fatigue, and unexplained bruising. Early diagnosis is challenging due to ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...

Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...

Fabhalta received its first FDA approval in December 2023 for adults with paroxysmal nocturnal hemoglobinuria (PNH). In the fourth quarter of 2024, Fabhalta generated sales of $57 million.

Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysis caused by C5 inhibitors in patients suffering from PNH while leaving intact the ...

(OMER), Friday announced that it has initiated clinical trial site activation for its Phase 3 program evaluating zaltenibart or OMS906 in paroxysmal nocturnal hemoglobinuria or PNH. The company ...